Paricalcitol
Paricalcitol is a synthetic vitamin D analog that binding to and activates the vitamin D receptor. It is primarily used to reduce parathyroid hormone (PTH) levels in chronic kidney disease patients, helping to manage mineral and bone disorder with a lower risk of causing hypercalcemia and hyperphosphatemia compared to calcitriol.
Dosage by Body Weight
Dosage must be strictly individualized and titrated based on serum intact parathyroid hormone (iPTH), calcium, and phosphorus levels. It can be administered orally (daily or three times a week) or intravenously during hemodialysis.
- Body Weight
- Below 5 kg
- Dose
- Not routine
- Frequency
- Not applicable
- Tracking Notes
- Safety and efficacy in pediatric patients under 5 kg have not been established. Use only under strict specialist supervision.
- Body Weight
- 5-7 kg
- Dose
- Individualized by specialist
- Frequency
- Determined by physician
- Tracking Notes
- Pediatric dosing is highly specialized and guided by iPTH and serum calcium levels rather than body weight.
- Body Weight
- 8-10 kg
- Dose
- Individualized by specialist
- Frequency
- Determined by physician
- Tracking Notes
- Dosing adjustments are based on periodic laboratory monitoring of calcium, phosphorus, and iPTH.
- Body Weight
- 11-15 kg
- Dose
- Individualized by specialist
- Frequency
- Determined by physician
- Tracking Notes
- Close monitoring by a pediatric nephrologist is required.
- Body Weight
- 16-20 kg
- Dose
- Individualized by specialist
- Frequency
- Determined by physician
- Tracking Notes
- Standard pediatric guidelines focus on baseline iPTH values for initial dosing rather than body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not routine | Not applicable | Safety and efficacy in pediatric patients under 5 kg have not been established. Use only under strict specialist supervision. |
| 5-7 kg | Individualized by specialist | Determined by physician | Pediatric dosing is highly specialized and guided by iPTH and serum calcium levels rather than body weight. |
| 8-10 kg | Individualized by specialist | Determined by physician | Dosing adjustments are based on periodic laboratory monitoring of calcium, phosphorus, and iPTH. |
| 11-15 kg | Individualized by specialist | Determined by physician | Close monitoring by a pediatric nephrologist is required. |
| 16-20 kg | Individualized by specialist | Determined by physician | Standard pediatric guidelines focus on baseline iPTH values for initial dosing rather than body weight. |
Formulation
Purpose
Prevention and treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) Stages 3, 4, and 5.
Generic Name
ParicalcitolBranded Drug Names
Paricalcitol is listed as a generic drug name. Common branded medicines that may contain the same active ingredient include:
Scheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.